New Modalities for Challenging Targets in Drug Discovery.

@article{Valeur2017NewMF,
  title={New Modalities for Challenging Targets in Drug Discovery.},
  author={E. Valeur and St{\'e}phanie M Gu{\'e}ret and H. Adihou and R. Gopalakrishnan and Malin Lemurell and H. Waldmann and T. Grossmann and A. Plowright},
  journal={Angewandte Chemie},
  year={2017},
  volume={56 35},
  pages={
          10294-10323
        }
}
Our ever-increasing understanding of biological systems is providing a range of exciting novel biological targets, whose modulation may enable novel therapeutic options for many diseases. These targets include protein-protein and protein-nucleic acid interactions, which are, however, often refractory to classical small-molecule approaches. Other types of molecules, or modalities, are therefore required to address these targets, which has led several academic research groups and pharmaceutical… Expand
Directing evolution: the next revolution in drug discovery?
TLDR
Recent advances in several areas, such as understanding of the biosynthetic pathways for natural products, synthetic biology and the development of biosensors to detect target molecules, are providing new opportunities to directly harness evolutionary pressure to identify and optimize compounds with desired bioactivities. Expand
Targeted Protein Degradation: from Chemical Biology to Drug Discovery.
TLDR
Small-molecule-induced proteolysis of selected substrates offers the potential of reaching beyond the limitations of the current pharmaceutical paradigm to expand the druggable target space. Expand
The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules
TLDR
An overview is provided on the evolving novel targets and molecular modalities, followed by a detailed analysis of the druggability aspects as well as the strategies used to progress drug candidate, and the trending chemistry and formulation techniques used to assess developability. Expand
Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs
TLDR
An up-to-date list of PPI targeting drugs that have been approved or are currently under clinical trial and have bound drug–target structures available is constructed and analyses suggest that developing a new rule would be beneficial for guiding PPI-drug discovery. Expand
De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits.
TLDR
Two purported peptide-based KRas inhibitors, SAH-SOS1 A and cyclorasin 9A5, exemplify false-positive molecules-in terms of both their binding affinities and cellular activities. Expand
Emerging modes-of-action in drug discovery.
TLDR
This review summarises emerging strategies to hijack cellular processes to modulate biological processes by highlighting the most representative examples of these approaches. Expand
The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations
TLDR
This review provides a brief description of novel biologics, including innovative antibody therapeutics, genetic modification technologies, new developments in vaccines, and multifunctional modalities, and provides an overview of the current CMC regulatory challenges. Expand
Inhibition of 14-3-3/Tau by Hybrid Small-Molecule Peptides Operating via Two Different Binding Modes
TLDR
Further efforts to optimize the binding mode and activity of the authors' modified Tau peptides through a combination of chemical synthesis, biochemical assays, and X-ray crystallography enhanced the understanding of the molecular parameters for inhibiting 14-3-3/Tau, which are important milestones toward the establishment of the 14- 3-3 PPI hypothesis. Expand
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
TLDR
This review focuses on nine diseases in three major therapeutics areas, diabetes, autoimmune, and neurological disorders, and provides a comprehensive overview of current and emerging therapeutic modalities developed in the recent years. Expand
Exploring new targets and chemical space with affinity selection-mass spectrometry
Affinity selection-mass spectrometry (AS-MS) is a high-throughput screening (HTS) technique for drug discovery that enables rapid screening of large collections of compounds to identify ligands for aExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 335 REFERENCES
Designed multiple ligands for cancer therapy.
TLDR
This review will provide an overview of reported designed multiple ligands for cancer and an exploration of the advantages and drawbacks of such compounds. Expand
Therapeutic Potential of Foldamers: From Chemical Biology Tools To Drug Candidates?
TLDR
The current knowledge of foldamers is reviewed in a drug discovery context and recent advances in the early phases of drug discovery including hit finding, target validation, and optimization and molecular modeling are discussed. Expand
Emerging Target Families: Intractable Targets.
  • S. Knapp
  • Biology, Medicine
  • Handbook of experimental pharmacology
  • 2016
TLDR
Progress made in developing inhibitors for challenging drug binding sites and emerging target families is summarized. Expand
The Future of Peptide‐based Drugs
The suite of currently used drugs can be divided into two categories – traditional ‘small molecule’ drugs with typical molecular weights of <500 Da but with oral bioavailability, and much largerExpand
Cell-permeable cyclic peptides from synthetic libraries inspired by natural products.
TLDR
The results demonstrate that many novel, cell permeable scaffolds exist beyond those found in extant natural products, and that such scaffolds can be rapidly identified using a combination of synthesis and deconvolution which can, in principle, be applied to any type of macrocyclic template. Expand
Multi-target therapeutics: when the whole is greater than the sum of the parts.
TLDR
The biological rationale for combination therapeutics is discussed, some existing combination drugs are reviewed, and a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit is presented. Expand
Induced protein degradation: an emerging drug discovery paradigm
TLDR
Induced protein degradation has the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins. Expand
Macrocycles in new drug discovery.
TLDR
The effects of macrocyclization upon potency, selectivity and physicochemical properties are discussed, concentrating on recent case histories in oncology drug discovery. Expand
Selection-based discovery of druglike macrocyclic peptides.
TLDR
This review discusses the use of ribosomal translation and in vitro selection techniques for the identification of bioactive macrocyclic peptides, emphasizing recent developments. Expand
Aptamer-Drug Conjugates.
TLDR
This Review will discuss ApDCs for targeted drug delivery in chemotherapy, gene therapy, immunotherapy, photodynamic therapy, and photothermal therapy, primarily of cancer. Expand
...
1
2
3
4
5
...